Ryan K. Shields, PharmD, MS

Resistance against this pathogen with β-lactamase medications can vary according to geographic region.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.

Carbapenem-resistant Enterobacterales present considerable treatment challenges. Recent cumulative evidence supports preference for therapies.

Recent study results show promising new modalities.

This approach can help with clinical outcomes and mortality, but resistance is not as well defined.

Ceftazidime-avibactam is a novel treatment for CRE infections, but reports of resistance are increasing.